학술논문
Effect of pregabalin initiation on diuretic requirements in patients with chronic heart failure.
Document Type
Academic Journal
Author
Source
Publisher: Elsevier Country of Publication: United States NLM ID: 101176252 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1544-3450 (Electronic) Linking ISSN: 10865802 NLM ISO Abbreviation: J Am Pharm Assoc (2003) Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Literature on pregabalin use in patients with heart failure is largely limited to patient case reports and cohort studies.
Objective: This study aimed to evaluate the effect of pregabalin initiation on diuretic requirements in patients with heart failure.
Methods: A retrospective analysis of patients with heart failure who were started on pregabalin between January 1, 2014, and September 1, 2021, at the Veterans Affairs North Texas Health Care System was used. The primary objective was to determine the median change in loop diuretic dose, in furosemide dose equivalents, 6 months after pregabalin initiation.
Results: Of 58 patients analyzed, there was no statistically significant difference in the primary outcome (P = 0.162). The secondary outcomes were found to be nonstatistically significant, and there was no correlation between pregabalin dose and outcomes.
Conclusion: This represents the largest analysis of diuretic dose requirements in patients with heart failure after initiation of pregabalin. Although there was no difference in the median change of diuretic dose prescribed, pregabalin should still be used with caution.
Competing Interests: Disclosure Dr Alvarez received funding from the National Institutes of Health (NIH). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the NIH under award number UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr Alvarez received grants not related to this project from Merck and Boehringer Ingelheim and was an advisory board member for Bayer. The authors declare no other relevant conflicts of interest or financial relationships.
(Published by Elsevier Inc.)
Objective: This study aimed to evaluate the effect of pregabalin initiation on diuretic requirements in patients with heart failure.
Methods: A retrospective analysis of patients with heart failure who were started on pregabalin between January 1, 2014, and September 1, 2021, at the Veterans Affairs North Texas Health Care System was used. The primary objective was to determine the median change in loop diuretic dose, in furosemide dose equivalents, 6 months after pregabalin initiation.
Results: Of 58 patients analyzed, there was no statistically significant difference in the primary outcome (P = 0.162). The secondary outcomes were found to be nonstatistically significant, and there was no correlation between pregabalin dose and outcomes.
Conclusion: This represents the largest analysis of diuretic dose requirements in patients with heart failure after initiation of pregabalin. Although there was no difference in the median change of diuretic dose prescribed, pregabalin should still be used with caution.
Competing Interests: Disclosure Dr Alvarez received funding from the National Institutes of Health (NIH). Research reported in this publication was supported by the National Center for Advancing Translational Sciences of the NIH under award number UL1TR001105. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Dr Alvarez received grants not related to this project from Merck and Boehringer Ingelheim and was an advisory board member for Bayer. The authors declare no other relevant conflicts of interest or financial relationships.
(Published by Elsevier Inc.)